Classification Criteria: Peripheral Spondyloarthropathy and Psoriatic Arthritis
- 799 Downloads
Recent proposals for re-classification of spondyloarthropathies according to the predominance of peripheral and axial manifestations and for non-radiographic ankylosing spondylitis to be re-named axial spondyloarthritis are reviewed. It is argued that such proposals are less likely to advance knowledge in the study of spondyloarthopathies and that accurate classification criteria for defined diseases, for example psoriatic arthritis, remain as necessary now as they ever did. The CASPAR criteria remain the best performing classification criteria for psoriatic arthritis.
KeywordsPsoriatic arthritis Spondyloarthritis Classification criteria Peripheral spondyloarthropathy
This work was supported by the facilities of the University of Otago and University of Queensland. Dr Taylor is a member of GRAPPA; Dr Robinson is an associate member of ASAS.
Conflict of Interest
Dr Taylor has consulted for Metabolex.
Dr Robinson declares that he has no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.PubMedCrossRefGoogle Scholar
- 3.•• Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31. This study proposes new classification criteria for SpA that have peripheral manifestations and potentially re-defines several diseases that fall under the SpA umbrella. Classification criteria that identify SpA in general are also defined by merging criteria for axial and peripheral SpA.PubMedCrossRefGoogle Scholar
- 5.Wright V, Moll JMH. Seronegative Polyarthritis. Amsterdam: North Holland Publishing Co.; 1976.Google Scholar
- 6.Burns T, Marder A, Becks E, Sullivan L, Calin A. Undifferentiated spondylarthritis: a nosological missing link? Arthritis Rheum. 1982;25(Suppl):s142.Google Scholar
- 11.Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rheum Mal Osteoartic. 1990;57(2):85–9.Google Scholar
- 12.Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770–6.PubMedCrossRefGoogle Scholar
- 16.• Bakland G, Alsing R, Singh K, Nossent JC. Assessment of spondyloarthritis international society criteria for axial spondyloarthritis in chronic back pain patients with high HLA B27 prevalence. Arthritis Care Res (Hoboken). 2012. Published online 25 July 2012. doi: 10.1002/acr.21804. Application of the axSpA criteria arm that uses HLA-B27 to identify patients leads to a high population prevalence of SpA. The prevalence of axSpA defined by HLA-B27 was 0.09% compared to a prevalence of 0.04% of radiographic axSpA.
- 17.•• Baeten D, Breban M, Lories R, Schett G, Sieper J. Spondyloarthritides: Related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65(1):12–20. Another useful review that discusses the difficult issue of exactly how different SpA diseases are related. PubMedCrossRefGoogle Scholar
- 23.• Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial Spondyloarthritis - A new disease entity, not necessarily early Ankylosing Spondylitis. Ann Rheum Dis. 2012; published online October 25, 2012. doi: 10.1136/annrheumdis-2012-202073. This paper reviews evidence that SpA with axial symptoms are far more heterogeneous than ankylosing spondylitis and suggests that it is premature to consider axSpA as the same disease as ankylosing spondylitis.
- 24.Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2012 published online July 7, 2012: doi: 10.1136/annrheumdis-2012-201766
- 25.Agency EM. CHMP post-authorisation summary of positive opinion for Humira 2012 [cited 2012 29 Nov 2012]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/smops/Positive/human_smop_000400.jsp&mid=WC0b01ac058001d127
- 28.•• van den Berg R, van Gaalen F, Helm VD, van Mil A, Huizinga T, van der Heijde D. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Ann Rheum Dis. 2012;71(8):1366–9. This useful study of early arthritis was able to clearly show that the CASPAR criteria for classifying psoriatic arthritis was more accurate than the new ASAS pSpA criteria and that all SpA criteria (ASAS, Amor, ESSG) have less than desirable sensitivity for classifying SpA in early disease.PubMedCrossRefGoogle Scholar